This MSLN-MUC16 interaction has been shown to be important for tumor cell adhesion and metastasis [15, 16] and is the main target of existing anti-MSLN immunotherapies [5, 12, 17–20], including anti-MSLN CAR T cell therapy. The gene discussed is MUC16; the disease is neoplasm.